RT Journal Article
SR Electronic
T1 Intra-arterial urokinase for acute ischemic stroke
JF Neurology
JO Neurology
FD Lippincott Williams & Wilkins
SP 1100
OP 1103
DO 10.1212/WNL.57.6.1100
VO 57
IS 6
A1 Tirschwell, D.L.
A1 Coplin, W.M.
A1 Becker, K.J.
A1 Vogelzang, P.
A1 Eskridge, J.
A1 Haynor, D.
A1 Cohen, W.
A1 Newell, D.
A1 Winn, H.R.
A1 Longstreth, W.T.
YR 2001
UL http://n.neurology.org/content/57/6/1100.abstract
AB The authors abstracted the records of 43 patients treated with intra-arterial urokinase for acute ischemic stroke to identify predictors of serious complications. Sixteen (37%) had such a complication. Higher urokinase dose (>1.5 × 106 U), higher mean arterial blood pressure before treatment (>130 mm Hg), basilar occlusive strokes, and severe strokes were most predictive of these complications. Although urokinase is no longer manufactured, these findings identify patients at risk for complications from other intra-arterial thrombolytics.